BACKGROUND: Advanced glycation end products (AGEs) are bioactive molecules found in greater concentrations in foods that have been processed at high temperatures. AGEs have been associated with impaired renal function in diabetes and in uremia. The relationship between AGEs and renal function in community-dwelling adults has not been well characterized. AIM OF THE STUDY: The objective was to determine whether plasma AGEs are independently associated with chronic kidney disease (CKD) and predictive of renal function in older adults. METHODS: The relationship between plasma carboxymethyl-lysine (CML), an AGE, and CKD (>or= stage 3 of National Kidney Foundation classification; estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2)) and eGFR at 3- and 6-years follow-up was examined in a population-based study of aging, the InCHIANTI study, in Tuscany, Italy. RESULTS: Of 1,008 adults, aged >or=65 years, 153 (15.2%) had CKD at enrollment. Mean (standard deviation [S.D.]) plasma CML was 365 (110) ng/ml. Plasma CML was associated with CKD (odds ratio [O.R.] expressed per 1 S.D., 1.53, 95% confidence interval [C.I.] 1.27-1.84, P < 0.0001) in a multivariate logistic regression model, adjusting for potential confounders. Plasma CML was associated with eGFR (beta = -2.77, standard error [S.E.] = 0.51, P < 0.0001) at baseline, 3-year (beta = -2.54, S.E. = 0.61, P < 0.0001) and 6-year follow-up visits (beta = -1.21, S.E. = 0.70, P = 0.08) in multivariate linear regression models, adjusting for potential confounders. The associations between plasma CML and prevalent CKD, eGFR, and eGFR at 3- and 6-year follow-up were significant and nearly unchanged after exclusion of adults with diabetes. CONCLUSION: Plasma CML is independently associated with CKD and is an independent predictor of decline in renal function in older community-dwelling adults.
BACKGROUND: Advanced glycation end products (AGEs) are bioactive molecules found in greater concentrations in foods that have been processed at high temperatures. AGEs have been associated with impaired renal function in diabetes and in uremia. The relationship between AGEs and renal function in community-dwelling adults has not been well characterized. AIM OF THE STUDY: The objective was to determine whether plasma AGEs are independently associated with chronic kidney disease (CKD) and predictive of renal function in older adults. METHODS: The relationship between plasma carboxymethyl-lysine (CML), an AGE, and CKD (>or= stage 3 of National Kidney Foundation classification; estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2)) and eGFR at 3- and 6-years follow-up was examined in a population-based study of aging, the InCHIANTI study, in Tuscany, Italy. RESULTS: Of 1,008 adults, aged >or=65 years, 153 (15.2%) had CKD at enrollment. Mean (standard deviation [S.D.]) plasma CML was 365 (110) ng/ml. Plasma CML was associated with CKD (odds ratio [O.R.] expressed per 1 S.D., 1.53, 95% confidence interval [C.I.] 1.27-1.84, P < 0.0001) in a multivariate logistic regression model, adjusting for potential confounders. Plasma CML was associated with eGFR (beta = -2.77, standard error [S.E.] = 0.51, P < 0.0001) at baseline, 3-year (beta = -2.54, S.E. = 0.61, P < 0.0001) and 6-year follow-up visits (beta = -1.21, S.E. = 0.70, P = 0.08) in multivariate linear regression models, adjusting for potential confounders. The associations between plasma CML and prevalent CKD, eGFR, and eGFR at 3- and 6-year follow-up were significant and nearly unchanged after exclusion of adults with diabetes. CONCLUSION: Plasma CML is independently associated with CKD and is an independent predictor of decline in renal function in older community-dwelling adults.
Authors: Thorsten P Degenhardt; Nathan L Alderson; David D Arrington; Robert J Beattie; John M Basgen; Michael W Steffes; Suzanne R Thorpe; John W Baynes Journal: Kidney Int Date: 2002-03 Impact factor: 10.612
Authors: L Ferrucci; S Bandinelli; E Benvenuti; A Di Iorio; C Macchi; T B Harris; J M Guralnik Journal: J Am Geriatr Soc Date: 2000-12 Impact factor: 5.562
Authors: W Kline Bolton; Daniel C Cattran; Mark E Williams; Sharon G Adler; Gerald B Appel; Kenneth Cartwright; Peter G Foiles; Barry I Freedman; Philip Raskin; Robert E Ratner; Bruce S Spinowitz; Frederick C Whittier; Jean-Paul Wuerth Journal: Am J Nephrol Date: 2003-12-17 Impact factor: 3.754
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh Journal: J Am Soc Nephrol Date: 2003-11 Impact factor: 10.121
Authors: Douglas Ganini; Marcelo Christoff; Marilyn Ehrenshaft; Maria B Kadiiska; Ronald P Mason; Etelvino J H Bechara Journal: Free Radic Biol Med Date: 2011-05-08 Impact factor: 7.376
Authors: Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jason M Kinchen; Casey M Rebholz; Josef Coresh; Andrew S Levey; Lesley A Inker; Michael Shlipak; Tanika N Kelly Journal: Metabolomics Date: 2019-11-13 Impact factor: 4.290
Authors: Nilam S Mangalmurti; Shampa Chatterjee; Guanjun Cheng; Emily Andersen; Aishat Mohammed; Donald L Siegel; Ann Marie Schmidt; Steven M Albelda; Janet S Lee Journal: Transfusion Date: 2010-11 Impact factor: 3.157
Authors: Pedro Gomes; Sónia Simão; Elisabete Silva; Vanda Pinto; João S Amaral; Joana Afonso; Maria Paula Serrão; Maria João Pinho; Patrício Soares-da-Silva Journal: Oxid Med Cell Longev Date: 2009 Jul-Aug Impact factor: 6.543